Description
The global biosimilar monoclonal antibodies market was valued at 5 billion in 2021, and it is expected to reach 8 billion with a CAGR of 9.9 % during the forecast period of 2022-2028. The prevalence of chronic disorders is expected to push the biosimilar monoclonal antibodies market. Biosimilar monoclonal antibodies treat chronic diseases such as cancer, autoimmune disease, and rheumatoid arthritis. Biosimilar monoclonal antibodies, like trastuzumab, bevacizumab, and rituximab, are utilized in cancer treatment. Moreover, the incidence of cancer is growing year by year. Therefore, most chronic diseases, including cancer, are expected to drive the biosimilar monoclonal antibodies market.
